Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Daraxonrasib→

Daraxonrasib PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2765081-21-6
Molecular formula
C44H58N8O5S
Molecular weight
811.06 g/mol
Drug class
RAS(ON) multi-selective inhibitortargeted antineoplastic small molecule
Mechanism of action
Inhibits active GTP-bound RAS G12X and wild-type RAS signalling across multiple RAS isoforms, suppressing downstream MAPK pathway signalling in RAS-driven tumours.
Indications / reported uses
  • Treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy under the US FDA RASONQUE indication approved 26 August 2026

Sources: US FDA — Approval of daraxonrasib for metastatic pancreatic adenocarcinoma, 26 August 2026 · FDA Orphan Drug database — Daraxonrasib · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

RAS(ON) multi-selective inhibitor; targeted antineoplastic small molecule

Mechanism of action

Inhibits active GTP-bound RAS G12X and wild-type RAS signalling across multiple RAS isoforms, suppressing downstream MAPK pathway signalling in RAS-driven tumours.

General use cases

  • Treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy under the US FDA RASONQUE indication approved 26 August 2026

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Daraxonrasib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Daraxonrasib Permitted Daily Exposure (PDE) report (the Daraxonrasib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Daraxonrasib Occupational Exposure Limit (OEL) report (the Daraxonrasib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.